Pimasertib + Dacarbazine
Phase 2Completed 0 watching 0 views this week⚡ Active
52
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
N-Ras Mutated Locally Advanced or Metastasis Malignant Cutaneous Melanoma
Conditions
N-Ras Mutated Locally Advanced or Metastasis Malignant Cutaneous Melanoma
Trial Timeline
Dec 5, 2012 → Oct 24, 2016
NCT ID
NCT01693068About Pimasertib + Dacarbazine
Pimasertib + Dacarbazine is a phase 2 stage product being developed by Merck for N-Ras Mutated Locally Advanced or Metastasis Malignant Cutaneous Melanoma. The current trial status is completed. This product is registered under clinical trial identifier NCT01693068. Target conditions include N-Ras Mutated Locally Advanced or Metastasis Malignant Cutaneous Melanoma.
Hype Score Breakdown
Clinical
17
Activity
12
Company
10
Novelty
5
Community
5
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT01693068 | Phase 2 | Completed |